COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach영국 웨일즈에서 50세 이상 성인의 COVID-19 백신 섭취 및 효과: 120만 인구 데이터 연결 코호트 접근법Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI Adult affected Alpha approach BNT162b2 ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines Characteristics Cohort collected data Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta dose doses Effectiveness estimate first dose followed by Hospital admission immunization Infection linkage of BNT162b2 Older outcome outcomes PCR positive PCR positive SARS-CoV-2 infection post vaccination predominant SARS-CoV-2 SARS-COV-2 infection schedule second dose Seven strain vaccination vaccination. Vaccine variants Wales [DOI] 10.1080/21645515.2022.2031774 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai populationArticle Published on 2022-12-312023-07-08 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), [키워드] AZD1222 ChAdOx1 COVID-19 vaccine immunogenicity Safety single-dose vaccine. [DOI] 10.1080/21645515.2022.2035573 PMC 바로가기
Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding DomainArticle Published on 2022-12-212023-07-10 Journal: Microbiology Spectrum [Category] COVID19(2023년), [키워드] Binding assays BNT162b2 ChAdOx1 COVID-19 neutralization tests SARS-CoV-2 sVNT. [DOI] 10.1128/spectrum.02669-22 PMC 바로가기
Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunityArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] appear Bayesian Beta ChAdOx1 Clinical efficacy Correlate of protection COVID-19 D614G Delta Delta VOC distribution Efficacy ENhance evaluate Evaluating finding Heterologous highlight homologous Immunity inversion Mix-match mRNA-1273 neutralizing antibody omicron pandemic phase 3 trial predicted Predictive previous study provide ranged reduction reductions in strain vaccination Vaccine variant Variant of concern. variants variants of concern VoC VOCs was used while Wuhan [DOI] 10.1016/j.vaccine.2022.10.011 PMC 바로가기
Potential mechanisms of vaccine-induced thrombosisArticle Published on 2022-11-012022-11-15 Journal: European journal of internal medicine [Category] 유전자 메커니즘, 진단, [키워드] activate Ad26.COV2.S Adenovirus administration AdV vector antibodies antibody Autoimmune heparin-induced thrombocytopenia B cell Bacteria BNT162b cerebral venous sinuse ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine characterized clinical conformational change Contact COVID-19 COVID-19 vaccine COVID-19 vaccines described develop Effectiveness elicited events expression Factors Gene therapy heparin-induced thrombocytopenia hexone immune complex immune response Immune thrombocytopenia immunothrombosis IMPROVE induce intrinsic knowledge laboratory feature mechanism monocyte occur PF4 Platelet Platelets Potential proinflammatory Protein receiving resulting Spike protein splice subject syndrome T-cell thrombosis Vaccine Vaccine- induced immune thrombocytopenia and thrombosis. vectors Venous thrombosis viruses [DOI] 10.1016/j.ejim.2022.08.002 PMC 바로가기
Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccinesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval Ad26.COV2-S Administered Admission adverse event adverse events adverse events. age analyzed anti-SARS-CoV-2 vaccine BNT162b2 calculated Campylobacter jejuni ChAdOx1 collected CoronaVac COVID-19 diarrhea died dose doses epidemiological Guillain-barrè syndrome immunization inactivated incidence interquartile range Intravenous immunoglobulin male median Mild mRNA-1273 mRNA-based Patient performed plasma positive provided recipient reported risk SARS-CoV-2 Seven Surveillance survivor symptom onset syndrome tested treated vaccination Vaccine Vaccines variant [DOI] 10.1111/ene.15504 PMC 바로가기
Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal StudyArticle Published on 2022-11-012022-11-16 Journal: Annals of laboratory medicine [Category] SARS, 변종, [키워드] acute respiratory syndrome analyzed anti-S antibody BNT162b2 BNT162b2 mRNA ChAdOx1 collected Concentration coronavirus Coronavirus disease-19 COVID-19 delta variant demonstrated dose doses Effectiveness Efficacy eight healthcare worker help immunogenicity longitudinal NAbs Neutralizing neutralizing antibody occurred omicron outbreak pandemic predicted produced Prospective PROTECT reached regimen risk second dose study period the vaccine Three-dose vaccination. university hospital vaccination vaccination rate variant variants of concern Wuhan-Hu-1 [DOI] 10.3343/alm.2022.42.6.688 PMC 바로가기
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)Article Published on 2022-11-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-RBD antibody B cell response BNT162b2 booster Cell-mediated immunity ChAdOx1 ChAdOx1 nCoV-19 comparable Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose elicit group humoral immunization Immunocompromised immunogenicity investigated IQR kidney transplant male median mononuclear cells mRNA mRNA-1273 mRNA-1273. no difference participant Peripheral blood positive Randomized Randomized controlled trial receive recipients response SARS-CoV-2 seroconversion rate significantly statistically T cell Vaccine Viral vector virus neutralization test [DOI] 10.1111/ajt.17151 PMC 바로가기
Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic reviewArticle Published on 2022-10-212022-11-15 Journal: Frontiers in Public Health [Category] 진단, [키워드] accompanied adverse event antibodies article autoantibodies autoantibody BNT162b2 ChAdOx1 Clinical course clinical feature complications composed conducted coronavirus disease coronavirus disease 2019 vaccine COVID-19 COVID-19 vaccination COVID-19 vaccine critical appraisal dermatomyositis Follow-up identify Immune-mediated IMPROVE independent induce Inflammatory inflammatory myopathy investigator Joanna Briggs Institute management muscular myositis myositis specific autoantibodies. occurred Onset Patient patients presenting proportion report reported Risk of bias SARS-CoV-2 SARS-CoV-2 vaccine searched Side effect skin rash Specific subtype Symptom systematic review Treatment vaccination Vaccine vaccine dose weakness were used [DOI] 10.3389/fpubh.2022.1007637 PMC 바로가기